cDC1 Prognostic and Predictive Role in Non-Small-Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors

University Hospital, Grenoble

Overview

The response rate of immune checkpoint inhibitors remains relatively low and the identification of the new predictive biomarkers is necessary. The rare population of cDC1 is very interesting, as its mouse counterparts is essential for the cross presentation of tumor-associated antigens, tumor immunity and response to immunotherapies. Their role in humans has not been studied. This proposal aims to study the prognostic role of cDC1 in a cohort of patients with advanced NSCLC, possibly demonstrating their positive predictive value of immune checkpoint inhibitors response.

Multicenter study aiming to collect patient's clinical data retrospectively and their histological samples prospectively. The cohort will include: * 30 patients PD-L1 \> 50% treated with pembrolizumab in first line and having a progression free survival ≥ 3 months * 30 patients PD-L1 \> 50% treated with pembrolizumab in first line and having a progression free survival \< 3 months * 30 patients PD-L1 \< 50% treated with cisplatin-based chemotherapy in first line

Study Type

OBSERVATIONAL

Conditions

Non Small Cell Lung Cancer

Interventions

This is a non-interventional studyOTHER

This is a non-interventional study

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * NSCLC diagnosis * Advanced disease (Stage III-IV) according to the TNM 7th/8th classification * Patients have to have performed pembrolizumab in first line if PD-L1 ≥ 50% or cisplastin-based chemotherapy if PD-L1 \< 50% * FFPE material available from diagnostic sample Exclusion Criteria: \-

Locations (1)

CHU Grenoble-Alpes

Grenoble, Isère, France

Outcomes

Primary Outcomes

Progression free survival (PFS)

To validate the cDC1 infiltration as predictive biomarker of pembrolizumab response

Time frame: 1 year

Secondary Outcomes

Overall response rate (ORR)

To compare the overall response rate (ORR) of cDC1-positive patients to cDC1 negative ones within those treated with pembrolizumab and on the entire cohort

Time frame: 1 year

Time to treatment failure (TTF)

To compare the time of treatment failure (TTF) on CDC1-positive patients to negatives ones within those treated with pembrolizumaband on the entire cohort

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.